文献速递临床试验与 GCP流行病学与生物统计

国际坏死性小肠结肠炎治疗试验核心结局指标集的开发——一项研究方案

Development of an international core outcome set for treatment trials in necrotizing enterocolitis-a study protocol.
PubMed 文献 · Trials · 2023-05-31

该研究方案旨在为确诊坏死性小肠结肠炎的早产儿治疗试验开发国际核心结局指标集(COS)。研究按COS-STAD建议和COMET手册设计,拟通过文献计量学方法邀请中低收入和高收入国家的125名临床医生和/或研究者,并通过当地患者组织邀请患者和家长,分为非专业人员、新生儿期和新生儿期后三个专家组,经过三轮在线德尔菲流程和一次面对面共识会议最终确定COS,并按COS-STAR声明报告。

要点

  • 坏死性小肠结肠炎干预研究在结局指标的选择、测量和报告上存在巨大异质性,阻碍荟萃分析和循证指南制定。
  • 该COS针对确诊坏死性小肠结肠炎的早产儿治疗试验设计,涵盖从诊断时刻到成年期对患者和医生最相关的结局。
  • 研究按COS-STAD建议和COMET手册设计,已获伦理审查委员会豁免并在COMET前瞻性注册(研究1920)。

核心结论

  • 开发国际核心结局指标集将有助于提高坏死性小肠结肠炎结局指标报告的同质性,使治疗策略的比较充分且高效,并有助于临床试验结果的解释和实施,从而为早产儿坏死性小肠结肠炎最佳治疗策略提供高质量证据。

研究设计与样本

  • 本研究为按照COS-STAD建议和COMET倡议手册设计的研究方案,已获伦理审查委员会豁免并在COMET前瞻性注册(研究1920)。
  • 拟基于科学产出(使用文献计量学工具SCIVAL)从中低收入和高收入国家邀请125名临床医生和/或研究者,并通过当地患者组织邀请患者和家长。
  • 参与者分为三个专家组:前患者和家长组(非专业组)、参与新生儿期工作的临床医生和研究者组(新生儿组)以及新生儿期后工作的临床医生和研究者组(新生儿期后组)。
  • 通过系统综述识别当前坏死性小肠结肠炎研究中使用的结局指标,在德尔菲流程中呈现给参与者,并从患者和家长视角识别符合条件的结局域。
  • 采用包括三轮在线德尔菲轮次和一次最终面对面共识会议的共识流程最终确定COS,最终COS按COS-STAR声明报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Necrotizing enterocolitis (NEC) is the most lethal disease of the gastrointestinal tract of preterm infants. New and existing management strategies need clinical evaluation. Large heterogeneity exists in the selection, measurement, and reporting of outcome measures in NEC intervention studies. This hampers meta-analyses and the development of evidence-based management guidelines. We aim to develop a Core Outcome Set (COS) for NEC that includes the most relevant outcomes for patients and physicians, from moment of diagnosis into adulthood. This COS is designed for use in NEC treatment trials, in infants with confirmed NEC. METHODS: This study is designed according to COS-STAD (Core Outcome Set-STAndards for Development) recommendations and the COMET (Core Outcome Measures in Effectiveness Trials) Initiative Handbook. We obtained a waiver from the Ethics Review Board and prospectively registered this study with COMET (Study 1920). We will approach 125 clinicians and/or researchers from low-middle and high-income countries based on their scientific output (using SCIVAL, a bibliometric tool). Patients and parents will be approached through local patient organisations. Participants will be separated into three panels, to assess differences in priorities between former patients and parents (1. lay panel), clinicians and researchers involved in the neonatal period (2. neonatal panel) and after the neonatal period (3. post-neonatal panel). They will be presented with outcomes currently used in NEC research, identified through a systematic review, in a Delphi process. Eligible outcome domains are also identified from the patients and parents' perspectives. Using a consensus process, including three online Delphi rounds and a final face-to-face consensus meeting, the COS will be finalised and include outcomes deemed essential to all stakeholders: health care professionals, parents and patients' representatives. The final COS will be reported in accordance with the COS-Standards for reporting (COS-STAR) statement. CONCLUSIONS: Development of an international COS will help to improve homogeneity of outcome measure reporting in NEC, will enable adequate and efficient comparison of treatment strategies, and will help the interpretation and implementation of clinical trial results. This will contribute to high-quality evidence regarding the best treatment strategy for NEC in preterm infants.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Klerk DH, van Varsseveld OC, Offringa M, et al. Development of an international core outcome set for treatment trials in necrotizing enterocolitis-a study protocol. Trials. 2023. PMID: 37259112. doi:10.1186/s13063-023-07413-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。